drugset / Trial / NCT06472713
Clinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic NPC
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, single-arm Phase 2 study to evaluate the efficacy and safety of mitoxantrone hydrochloride liposome injection combined with PD-1 blockade in patients with recurrent (not unable to locally curative treatment) or metastatic NPC who failed at least first-line platinum-containing standard regimen and/or anti PD-1/L1.
Timeline
- Start
- 2024-07-20
- Primary completion
- 2025-10-31
- Completion
- 2027-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mitoxantrone | Small molecule | 30 mg | — |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | — |
| Subject | Toripalimab | Monoclonal antibody | 240 mg | — |
| Subject | carrellimab | Monoclonal antibody | 200 mg | — |